Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 122

Similar articles for PubMed (Select 24262762)

1.

Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study).

Van Tassell BW, Arena R, Biondi-Zoccai G, McNair Canada J, Oddi C, Abouzaki NA, Jahangiri A, Falcao RA, Kontos MC, Shah KB, Voelkel NF, Dinarello CA, Abbate A.

Am J Cardiol. 2014 Jan 15;113(2):321-7. doi: 10.1016/j.amjcard.2013.08.047. Epub 2013 Oct 4.

PMID:
24262762
2.

Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study].

Abbate A, Van Tassell BW, Biondi-Zoccai G, Kontos MC, Grizzard JD, Spillman DW, Oddi C, Roberts CS, Melchior RD, Mueller GH, Abouzaki NA, Rengel LR, Varma A, Gambill ML, Falcao RA, Voelkel NF, Dinarello CA, Vetrovec GW.

Am J Cardiol. 2013 May 15;111(10):1394-400. doi: 10.1016/j.amjcard.2013.01.287. Epub 2013 Feb 27.

3.

Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study).

Abbate A, Kontos MC, Grizzard JD, Biondi-Zoccai GG, Van Tassell BW, Robati R, Roach LM, Arena RA, Roberts CS, Varma A, Gelwix CC, Salloum FN, Hastillo A, Dinarello CA, Vetrovec GW; VCU-ART Investigators.

Am J Cardiol. 2010 May 15;105(10):1371-1377.e1. doi: 10.1016/j.amjcard.2009.12.059. Epub 2010 Apr 2.

PMID:
20451681
4.

A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility.

Kitzman DW, Hundley WG, Brubaker PH, Morgan TM, Moore JB, Stewart KP, Little WC.

Circ Heart Fail. 2010 Jul;3(4):477-85. doi: 10.1161/CIRCHEARTFAILURE.109.898916. Epub 2010 Jun 1.

5.

Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O'Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E; RELAX Trial.

JAMA. 2013 Mar 27;309(12):1268-77. doi: 10.1001/jama.2013.2024.

6.

Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial.

von Haehling S, Schefold JC, Jankowska EA, Springer J, Vazir A, Kalra PR, Sandek A, Fauler G, Stojakovic T, Trauner M, Ponikowski P, Volk HD, Doehner W, Coats AJ, Poole-Wilson PA, Anker SD.

J Am Coll Cardiol. 2012 Feb 7;59(6):585-92. doi: 10.1016/j.jacc.2011.10.880.

7.

Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial.

Edelmann F, Gelbrich G, Duvinage A, Stahrenberg R, Behrens A, Prettin C, Kraigher-Krainer E, Schmidt AG, Düngen HD, Kamke W, Tschöpe C, Herrmann-Lingen C, Halle M, Hasenfuss G, Wachter R, Pieske B.

Int J Cardiol. 2013 Nov 30;169(6):408-17. doi: 10.1016/j.ijcard.2013.10.018. Epub 2013 Oct 11.

8.

Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction.

Zamani P, Rawat D, Shiva-Kumar P, Geraci S, Bhuva R, Konda P, Doulias PT, Ischiropoulos H, Townsend RR, Margulies KB, Cappola TP, Poole DC, Chirinos JA.

Circulation. 2015 Jan 27;131(4):371-80; discussion 380. doi: 10.1161/CIRCULATIONAHA.114.012957. Epub 2014 Dec 22.

PMID:
25533966
9.

Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure.

Van Tassell BW, Arena RA, Toldo S, Mezzaroma E, Azam T, Seropian IM, Shah K, Canada J, Voelkel NF, Dinarello CA, Abbate A.

PLoS One. 2012;7(3):e33438. doi: 10.1371/journal.pone.0033438. Epub 2012 Mar 16.

10.

Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels.

Mayer B, Holmer SR, Hengstenberg C, Lieb W, Pfeifer M, Schunkert H.

Int J Cardiol. 2005 Aug 18;103(2):182-6.

PMID:
16080978
11.

Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study.

Chevalier X, Goupille P, Beaulieu AD, Burch FX, Bensen WG, Conrozier T, Loeuille D, Kivitz AJ, Silver D, Appleton BE.

Arthritis Rheum. 2009 Mar 15;61(3):344-52. doi: 10.1002/art.24096.

12.

Impaired aerobic capacity and physical functional performance in older heart failure patients with preserved ejection fraction: role of lean body mass.

Haykowsky MJ, Brubaker PH, Morgan TM, Kritchevsky S, Eggebeen J, Kitzman DW.

J Gerontol A Biol Sci Med Sci. 2013 Aug;68(8):968-75. doi: 10.1093/gerona/glt011. Epub 2013 Mar 22.

13.

Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial.

Kitzman DW, Brubaker PH, Morgan TM, Stewart KP, Little WC.

Circ Heart Fail. 2010 Nov;3(6):659-67. doi: 10.1161/CIRCHEARTFAILURE.110.958785. Epub 2010 Sep 17.

14.

Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators.

Lang RM, Elkayam U, Yellen LG, Krauss D, McKelvie RS, Vaughan DE, Ney DE, Makris L, Chang PI.

J Am Coll Cardiol. 1997 Oct;30(4):983-91.

PMID:
9316528
15.

Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction.

Zile MR, Bourge RC, Redfield MM, Zhou D, Baicu CF, Little WC.

JACC Heart Fail. 2014 Apr;2(2):123-30. doi: 10.1016/j.jchf.2013.12.002. Epub 2014 Feb 26.

PMID:
24720918
16.

A mechanistic investigation of ACE inhibitor dose effects on aerobic exercise capacity in heart failure patients.

Cooke GA, Williams SG, Marshall P, Al-Timman JK, Shelbourne J, Wright DJ, Tan LB.

Eur Heart J. 2002 Sep;23(17):1360-8.

PMID:
12191747
17.

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.

Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS; Type 1 Diabetes TrialNet Canakinumab Study Group, Pickersgill L, de Koning E, Ziegler AG, Böehm B, Badenhoop K, Schloot N, Bak JF, Pozzilli P, Mauricio D, Donath MY, Castaño L, Wägner A, Lervang HH, Perrild H, Mandrup-Poulsen T; AIDA Study Group.

Lancet. 2013 Jun 1;381(9881):1905-15. doi: 10.1016/S0140-6736(13)60023-9. Epub 2013 Apr 5.

18.

A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction.

Parthasarathy HK, Pieske B, Weisskopf M, Andrews CD, Brunel P, Struthers AD, MacDonald TM.

Eur J Heart Fail. 2009 Oct;11(10):980-9. doi: 10.1093/eurjhf/hfp120.

19.

A multicentre, double-blind, placebo-controlled trial of quinapril in mild, chronic heart failure.

Northridge DB, Rose E, Raftery ED, Lahiri A, Elder AT, Shaw TR, Henderson E, Dargie HJ.

Eur Heart J. 1993 Mar;14(3):403-9.

PMID:
8458362
20.

Effect of valsartan on systemic right ventricular function: a double-blind, randomized, placebo-controlled pilot trial.

van der Bom T, Winter MM, Bouma BJ, Groenink M, Vliegen HW, Pieper PG, van Dijk AP, Sieswerda GT, Roos-Hesselink JW, Zwinderman AH, Mulder BJ.

Circulation. 2013 Jan 22;127(3):322-30. doi: 10.1161/CIRCULATIONAHA.112.135392. Epub 2012 Dec 17.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk